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Abstract
Sequential Multiple Assignment Randomized Trials (SMARTs) are considered the gold
standard for estimation and evaluation of treatment regimes. SMARTs are typically
sized to ensure sufficient power for a simple comparison, e.g., the comparison of two
fixed treatment sequences. Estimation of an optimal treatment regime is conducted as
part of a secondary and hypothesis-generating analysis with formal evaluation of the
estimated optimal regime deferred to a follow-up trial. However, running a follow-up
trial to evaluate an estimated optimal treatment regime is costly and time-consuming;
furthermore, the estimated optimal regime that is to be evaluated in such a follow-up
trial may be far from optimal if the original trial was underpowered for estimation of
an optimal regime. We derive sample size procedures for a SMART that ensure: (i)
sufficient power for comparing the optimal treatment regime with standard of care; and
(ii) the estimated optimal regime is within a given tolerance of the true optimal regime
with high-probability. We establish asymptotic validity of the proposed procedures
and demonstrate their finite sample performance in a series of simulation experiments.
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1 Introduction
A treatment regime is a sequence of functions, one per stage of clinical intervention, that
map up-to-date patient information to a recommended treatment. An optimal treatment
regime maximizes the mean of some cumulative clinical outcome when applied to select
treatments for individuals in a population of interest (Murphy, 2003; Robins, 2004). Thus,
an optimal treatment regime leads to better overall healthcare by adapting treatment to the
evolving health status of each patient; consequently, optimal treatment regimes have become
a primary means of operationalizing precision medicine. Optimal treatment regimes have
been estimated across a wide range of application domains including breastfeeding (Moodie
et al., 2012), bipolar disorder (Wu et al., 2015; Zhang et al., 2017), cancer (Thall et al.,
2000; Zhao et al., 2011; Wang et al., 2012; Zhang et al., 2012, 2015; Murray et al., 2017),
cystic fibrosis (Zhou et al., 2017), diabetes (Ertefaie, 2014; Luckett et al., 2016), depression
(Zhao et al., 2012), HIV (Moodie et al., 2007; van der Laan et al., 2005; Cain et al., 2010),
smoking cessation (Chakraborty et al., 2009), substance abuse (Nahum-Shani et al., 2017)
among others.
Sequential Randomized Multiple Assignment Randomized Trials (SMARTs Lavori and
Dawson, 2000, 2004; Murphy, 2005a; Kidwell, 2014) are the gold standard for estimating
and evaluating treatment regimes (Murphy et al., 2007; Lei et al., 2012; Chakraborty and
Moodie, 2013; Kosorok and Moodie, 2015) and are increasingly common design in clinical
and intervention science (PSU Methodology Center, 2017b,a). However, sample size calcu-
lations for SMARTs are typically based on power calculations for simple comparisons, e.g.,
comparison of the mean outcome across two pre-specified treatment sequences (Murphy,
2005a; Lei et al., 2012) and estimation of an optimal treatment regime from data collected
in a SMART are almost always (we are not aware of an exception) conducted as part of
exploratory, hypothesis-generating analyses. This approach is aligned with the estimate-
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and-validate paradigm wherein: (i) an optimal treatment regime is estimated using data
collected in a SMART; and (ii) the performance of the estimated optimal regime is validated
in a follow-up trial where the estimated regime is compared head-to-head with standard of
care (Murphy, 2005a). This approach is appealing in that it avoids a number of nontrivial
technical issues associated with estimating and evaluating a treatment regime using the same
data (Robins, 2004; Moodie et al., 2010; bib, 2009; Song et al., 2011; Chakraborty et al., 2014;
Laber et al., 2014); furthermore, sample size formulae for the comparison of fixed treatment
sequences or other commonly used criteria to size SMARTs are straightforward in that they
resemble those commonly used in non-sequential randomized trials. Another reason that
sample size calculations for SMARTs are often based on simple comparisons is the seemingly
widely held belief that sizing a trial to guarantee frequentist operating characteristics for an
estimated optimal regime, e.g., providing a performance guarantee for the estimated regime
or powering a comparison of the performance of the optimal regime with standard of care,
would either: (i) require a prohibitively large sample size; and/or (ii) rely on unrealistic
assumptions about the underlying data-generating model. We provide evidence that for a
for a large class of generative models neither of these beliefs appear to be well-founded.
We derive sample size procedures for a SMART that ensure sufficient power in comparing
the mean outcome under the optimal regime with standard of care and that the estimated
optimal regime will be within a given tolerance of the optimal policy with a given probabil-
ity. The proposed sample sized procedures we develop here are at two possible extremes in
terms of modeling assumptions. Our first procedure imposes significant parametric structure
on the data-generating model and consequently we are able to derive sample size formulae
that resemble the comparison of two means and require elicitation or estimation of a single
scalar parameter. Our second procedure imposes structure only on moments and tail be-
havior of some components of the data generating model and then uses the bootstrap with
oversampling to estimate a sufficient sample size; as this procedure imposes less structure
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the resulting estimator is more variable and consequently the estimated sample size tends to
be larger. One reason for considering these two extremes is that they provide a basis for in-
termediate procedures that impose as much structure, as appropriate for a given application.
We leave such intermediate approaches to future work.
We perceive the proposed work as making the following contributions: (i) it provides
the first rigorous yet practical sample size procedures for estimating and evaluating optimal
treatment regimes using SMARTs; (ii) it generates new knowledge about how much addi-
tional data would be needed to estimate a high-quality regime and consequently a provides a
sense of how ‘underpowered’ existing SMARTs are for estimating optimal treatment regimes;
and (iii) it provides theoretical guarantees for bootstrap oversampling for sample size calcu-
lations that are of independent interest. Furthermore, the proposed criteria used to derive
our samples size procedures are closely related to those used in Laber et al. (2015) to size
a single stage two-arm trial to estimate an optimal regime, however, the current procedure
applies to multistage trials and provides considerably stronger performance guarantees for
the estimated optimal regime.
In Section 2, we provide the setup and notation. In Section 3, we derive our sample size
procedures and state their theoretical properties. In Section 4, we evaluate the finite sample
performance of the proposed sample size procedures in a series of simulation experiments.
A discussion of the proposed methodology and open problems is provided in Section 5.
2 Setup and notation
We consider choosing the sample size, n, for a two-stage SMART that will produce data,
Dn = {(X1,i, A1,i,X2,i, A2,i, Yi)}ni=1, which comprises i.i.d. trajectories of the form (X1, A1,
X2, A2, Y ) where: X1 ∈ Rp1 denotes baseline subject information; A1 ∈ {−1, 1} denotes the
first assigned treatment; X2 ∈ Rp2 denotes subject information collected during the course of
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the first treatment; A2 ∈ {−1, 1} denotes the second assigned treatment; and Y ∈ R denotes
the outcome, coded so that higher is better. Define H1 = X1 and H2 = (X
ᵀ
1, A1,X
ᵀ
2)
ᵀ
so that H t denotes the history at time t = 1, 2. For simplicity, we assume that the trial
will employ simple one-to-one randomization so that P (At = at|H t) = 1/2 with probability
one for at ∈ {−1, 1} , t = 1, 2; extensions to more complex randomization schemes including
those with feasible sets of treatments is straightforward (Schulte et al., 2014). A treatment
regime in this context is a pair of functions pi = (pi1, pi2) where pit : domH t → domAt so that
a decision maker following pi would recommend treatment pit(ht) to a patient presenting with
H t = ht at time t = 1, 2. We define a treatment regime as optimal if it leads to maximal
mean outcome if applied to the population from which Dn is drawn (other definitions of
optimality are possible, see Kosorok and Moodie, 2015; Linn et al., 2016). To formally define
an optimal treatment regime, we use potential outcomes (Rubin, 1978; Splawa-Neyman et al.,
1990).
Let H∗2(a1) denote the potential second history under initial treatment a1 and Y
∗(a1, a2)
the potential outcome under treatment sequence (a1, a2). The potential outcome under a
regime pi is
Y ∗(pi) =
∑
(a1,a2)
Y ∗(a1, a2)1pi1(H1)=a11pi2{H∗2(a1)}=a2 ,
where 1u is an indicator that u is true. For any regime, pi, define V (pi) = EY ∗(pi); an optimal
regime, piopt, satisfies V (piopt) ≥ V (pi) for all pi. Our sample size procedures depend on an
estimator of piopt, in order to construct such an estimator, we make the following assumptions:
(C1) sequential ignorability,
{
H∗2(a1), Y
∗(a1, a2) : (a1, a2) ∈ {−1, 1}2
} ⊥ At|H t for t = 1, 2;
(C2) positivity, P (At = at|H t) > 0 with probability one for each at ∈ {−1, 1} for t = 1, 2;
and (C3) consistency, Y = Y ∗(A1, A2) and H2 = H∗2(A1). These assumptions are standard
in the context of estimating optimal treatment regimes (Robins, 2004; Schulte et al., 2014;
Chakraborty and Moodie, 2013) with (C1) and (C2) holding by design in a SMART.
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Under these assumptions, the optimal regime can be characterized in terms of the data-
generating model as follows. Define Q2(h2, a2) = E(Y |H2 = h2, A2 = a2) and Q1(h1, a1) =
E {maxa2 Q2(H2, a2)|H1 = h1, A1 = a1}, then pioptt (ht) = arg maxat Qt(ht, at) for t = 1, 2
(see Murphy, 2005b; Schulte et al., 2014). Furthermore, it can be seen that V (piopt) =
Emaxa1 Q1(H1, a1). Our sample size procedures are based on constructing estimators of
Qt(h1, at) for t = 1, 2 and subsequently deriving plug-in estimators of pi; these procedures
vary in the structure we impose on these functions. Before describing specific estimators, we
state properties of these estimators that we would like to ensure hold with high-probability
provided the sample size is sufficiently large.
Let pin denote an estimator of pi
opt and let B0 > 0, γ, α, η, , ζ ∈ (0, 1) be constants. Our
goal is to choose n so that:
(POW) there exists an α-level test of H0 : V (pi
opt) ≤ B0 based on pin that has power at least
(1− γ)× 100 + o(1) provided V (piopt) ≥ B0 + η;
(OPT) P [E {Y ∗(pin)|Dn} ≥ V (piopt)− ] ≥ 1− ζ + o(1).
Condition (POW) ensures sufficient power to test the effectiveness of the optimal treatment
regime relative to some baseline expected outcome, B0, e.g., the expected outcome under
some standard of care. Condition (OPT) ensures that the expected performance of the es-
timated optimal regime will be near-optimal with high-probability. These conditions are
analogous to those used to size a one-stage clinical trial for estimation of an optimal regime
except that (OPT) controls the performance of the estimated optimal regime whereas Laber
et al. (2015) control the estimated performance of the estimated optimal regime. Further-
more, like the one-stage setting, our sample size procedures depend on approximating the
sampling distribution of an estimator of EY ∗(piopt); however, as we will later illustrate, con-
structing a high-quality approximation is markedly more complex in the multistage setting
(see also Dawid, 1994; Chakraborty et al., 2009; Moodie et al., 2010; Hirano and Porter,
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2012; Chakraborty et al., 2014; Laber et al., 2014; Luedtke and Van Der Laan, 2016).
3 Sample size procedures
We derive two sample size procedures. The first procedure imposes more parametric structure
on the joint distribution of (X1, A1,X2, A2, Y ) than is typical in Q-learning and thereby
avoids (or rather assumes away) some of the complexities associated with non-regularity and
exceptional laws (Robins, 2004; Chakraborty et al., 2009; Moodie et al., 2010; Chakraborty
et al., 2013, 2014; Laber et al., 2014; Song et al., 2015). The second proposed procedure
does not impose as much parametric structure but at the expense of a more complex and
potentially conservative sample size estimator.
3.1 Normality-based sample size procedure
We make the following assumptions about the generative model:
(AN1) Q2(h2, a2) = h
ᵀ
2,0β
∗
2,0 + a2h
ᵀ
2,1β
∗
2,1, where h2,0 ∈ Rp2,0 ,h2,1 ∈ Rp2,1 are summaries of h2
and β∗2,0 ∈ Rp2,0 , β∗2,1 ∈ Rp2,1 are unknown parameters;
(AN2) E
(
Hᵀ2,0β
∗
2,0|H1 = h1, A1 = a1
)
= hᵀ1,0ξ
∗
1,0 + a1h
ᵀ
1,1ξ
∗
1,1, where h1,0 ∈ Rp1,0 ,h1,1 ∈ Rp1,1
are summaries of h1 and ξ
∗
1,0 ∈ Rp1,0 , ξ∗1,1 ∈ Rp1,1 are unknown parameters;
(AN3) Hᵀ2,1β
∗
2,1 = H
ᵀ
1,2$
∗
1,2 + A1H
ᵀ
1,3$
∗
1,3 + τ
∗Z, where H1,2 ∈ Rp1,2 ,H1,3 ∈ Rp1,3 are sum-
maries of H1, Z is a standard normal random variable which is independent of H1, A1,
and τ ∗ > 0, $∗1,2 ∈ Rp1,2 , $∗1,3 ∈ Rp1,3 , are unknown parameters;
(AN4)
(
Hᵀ1,0ξ
∗
1,0,H
ᵀ
1,1ξ
∗
1,1,H
ᵀ
1,2$
∗
1,2,H
ᵀ
1,3$
∗
1,3
)ᵀ ∼ Normal(ω∗,Ω∗), where ω∗ ∈ R4 and Ω∗ ∈
R4×4 are unknown parameters.
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Assumptions (AN1)-(AN3) are similar to those used in interactive Q-learning (IQ-learning
Laber et al., 2014) except that in IQ-learning, (AN3) is replaced with a more general location-
scale model than the normal linear model used here. The summaries of the history ht for
t = 1, 2 can include basis expansions or other non-linear terms as needed. These assumptions
were motivated by a desire to create a generative model that is conceptually consistent
with the analysis model used in linear Q-learning which remains the most commonly used
method for estimating an optimal treatment regime from SMARTs. Assumption (AN4) is
not required by IQ-learning as it conditions on H1. The assumption of joint normality could
be relaxed, for example, by using a copula or semi-parametric model, but at the expense of
more complex expressions that are less amenable to sample size calculations. Therefore we
shall not consider such generalizations further.
The following results, which are proved in the Supplemental Materials, will be used to
inform the construction of an estimator of the optimal treatment regime (see Schulte et al.,
2014; Laber et al., 2014, for related expressions). Let Φ denote the cumulative distribution
function of a standard normal random variable.
Lemma 3.1. Assume (AN1)-(AN3). For any β1 = (ξ
ᵀ
1,0, ξ
ᵀ
1,1, $
ᵀ
1,2, $
ᵀ
1,3)
ᵀ define
Q1(h1, a1; β1, τ) = h
ᵀ
1,0β1,0 + a1h
ᵀ
1,1β1,1 +
2τ√
2pi
exp
{
−
(
hᵀ1,2β1,2 + a1h
ᵀ
1,3β1,3
)2
2τ 2
}
+
(
hᵀ1,2β1,2 + a1h
ᵀ
1,3β1,3
) [
1− 2Φ
{
−
(
hᵀ1,2β1,2 + a1h
ᵀ
1,3β1,3
)
τ
}]
.
Then, Q1(h1, a1) = Q1(h1, a1; β
∗
1 , τ
∗).
Let W (H1, β1) = (H
ᵀ
1,0ξ1,0,H
ᵀ
1,1ξ1,1,H
ᵀ
1,2$1,2,H
ᵀ
1,3$1,3)
ᵀ and define g : R4 → R as
g(v) = max
ρ∈{−1,1}
(
v1 + ρv2 +
1√
2pi
exp
{
−(v3 + ρv4)
2
2
}
+ (v3 + ρv4) [1− 2Φ{− (v3 + ρv4)}]
)
;
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it follows from Lemma (3.1) that maxa1 Q1(H1, a1) = τ
∗g {W (H1, β∗1)/τ ∗}. Let ψ(v;ω,Ω)
denote the density of a multivariate normal distribution with mean ω ∈ R4 and covariance
Ω ∈ R4×4 and write vech(Σ) to denote the vector-half operator of symmetric matrix Σ
(Henderson and Searle, 1979). The following result shows that V (piopt) is a smooth function
of ω∗, τ ∗, and Ω∗.
Corollary 3.2. Assume (AN1)-(AN4) and let g : R4 → R be defined as above. Then
V (piopt) = ν {τ ∗, ω∗, vech(Ω∗)} =
∫
R4
τ ∗g (v/τ ∗)ψ(v;ω∗,Ω∗)dv.
Thus, given estimators τ̂n, ω̂n, and Ω̂n of τ
∗, ω∗, and Ω∗, one can use the preceding result to
construct a plugin estimator of V (piopt). We next describe how to construct these estimators.
Let Pn denote the empirical measure. Define Q2(h2, a2; β2) = hᵀ2,0β2,0 + a2h
ᵀ
2,1β2,1
and subsequently define β̂2,n = arg minβ2 Pn {Y −Q2(H2, A2; β2)}2. Thus, Q̂2,n(h2, a2) =
Q2(h2, a2; β̂2,n) and the estimated optimal rule at the second stage is pi2,n(h2) = arg maxa2 Q̂2,n(h2, a2).
Define
ξ̂1,0,n, ξ̂1,1,n = arg min
ξ1,0,ξ1,1
Pn
(
Hᵀ2,0β̂2,0,n −Hᵀ1,0ξ1,0 − A1Hᵀ1,1ξ1,1
)2
$̂1,2,n, $̂1,3,n = arg min
$1,2,$1,3
Pn
(
Hᵀ2,1β̂2,1,n −Hᵀ1,2$1,2 − A1Hᵀ1,3$1,3
)2
so that β̂1,n = (ξ̂
ᵀ
1,0,n, ξ̂
ᵀ
1,1,n, $̂
ᵀ
1,2,n, $̂
ᵀ
1,3,n)
ᵀ is the least-squares estimator of β∗1 = (ξ
∗ᵀ
1,0, ξ
∗ᵀ
1,1,
$∗ᵀ1,2, $
∗ᵀ
1,3)
ᵀ. In addition, define τ̂ 2n = Pn
{
Hᵀ2,1β̂2,1 −Hᵀ1,2$̂1,2,n − A1Hᵀ1,3$̂1,3,n
}2
. The plu-
gin estimator of Q1(h1, a1), based on (3.1), is Q̂1,n(h1, a1) = Q1(h1, a1; β̂1,n, τ̂n) and the esti-
mated optimal decision rule at the first stage is pi1,n(h1) = arg maxa1 Q̂1,n(h1, a1). Further-
more, define ω̂n = PnW (H1, β̂1,n) and Ω̂n = Pn
{
W (H1, β̂1,n)− ω̂n
}{
W (H1, β̂1,n)− ω̂n
}ᵀ
.
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The plugin estimator of V (piopt) is
V̂n = ν
{
τ̂n, ω̂n, vech
(
Ω̂n
)}
=
∫
R4
τ̂ng (v/τ̂n)ψ(v; ω̂n, Ω̂n)dv.
To establish consistency and asymptotic normality of V̂n we assume:
(AN5) {τ ∗, ω∗ᵀ, vech(Ω∗)}ᵀ ∈ Θ ⊆ R15, where Θ is compact;
(AN6)
√
n
[{
τ̂n, ω̂
ᵀ
n, vech(Ω̂n)
ᵀ
}ᵀ
− {τ ∗, ω∗ᵀ, vech(Ω∗)ᵀ}ᵀ
]
 Normal(0,Σ∗), where Σ∗ ∈ R15×15
is positive definite.
Condition (AN6) follows from moment conditions that are common in M -estimation; we
provide sufficient conditions for (AN6) in the Supplemental Materials.
Lemma 3.3. Assume (C1)-(C3) and (AN1)-(AN6). Then,
√
n
{
V̂n − V (piopt)
}
 Normal
(
0, σ∗2
)
,
where σ∗2 = ∇ν {τ ∗, ω∗, vech(Ω∗)}ᵀΣ∇ν {τ ∗, ω∗, vech(Ω∗)}.
Let σ̂2n be a consistent estimator of σ
∗2 and let z1−% the (1 − %) quantile of a standard
normal distribution, then a test that rejects when
√
n
{
V̂n −B0
}
/σ̂n ≥ z1−α is an (asymp-
totic) α-level test of H0 : V (pi
opt) ≤ B0 with power exceeding Φ(zα +
√
nη/σ∗) + o(1) when
V (piopt) ≥ B0 + η. Thus, choosing n =
⌈
(σ∗2/η2) {Φ−1(1− γ) + z1−α}2
⌉
, satisfies (POW)
asymptotically. This expression depends on σ∗, which is unknown in general, thus, a value
for σ∗ must be elicited from domain experts or estimated from historical data.
The preceding sample size has a familiar form which is unsurprising as it is derived from
a test statistic which is asymptotically normal. However, what is perhaps more surprising,
is that a similar sample size formula can also be used to ensure that condition (OPT)
holds under the following regularity conditions. Define ∆Qj = Qj(Hj, 1)−Qj(Hj,−1) and
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∆Q̂j,n = Q̂j,n(Hj, 1) − Q̂j,n(Hj,−1) for j = 1, 2. To select n so that (OPT) also holds we
further assume:
(AN7) there exists positive sequences {cn,j}n≥1 and {`n,j}n≥1 satisfying lim infn→∞ cn,j ≥
c0,j > 0 and lim infn→∞ `n,j ≥ `0,j > 0 such that
P
{√
n|∆Q̂j −∆Qj| > t
}
≤ exp (−cn,jt`n,j) ,
for all n and j = 1, 2;
(AN8) there exists Mj, κj > 0 such that P (|∆Qj|≤ ) ≤Mjκj for j = 1, 2 as → 0.
The preceding assumptions are relatively mild with (AN7) being weaker than requiring a
subexponetial tail; e.g., (AN7) and (AN8) would be satisfied if the histories and outcomes are
normally distributed. The following result characterizes the concentration of the marginal
mean outcome under pin about pi
opt which can subsequently be used to choose a sample size
n that satisfies (OPT).
Lemma 3.4. Assume (C1)-(C3) and (AN1)-(AN8). Then there exists K and δ > 0 such
that
|V (pin)− V (piopt)|≤ Kn−δ|V̂n − V (piopt)|+op(1/
√
n).
Corollary 3.5. Assume (C1)-(C3) and (AN1)-(AN8). Then setting
n =
⌈{
Φ−1(1− ζ)σ∗

}2⌉
,
satisfies (OPT).
Remark 3.6. Given pilot or historical data, one can construct a plug-in estimator of σ∗2. In
the absence of such data, one can use an elicited value for the variance of Y under standard
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care as an ad hoc surrogate for σ∗2. Heuristic justification for this surrogate is as follows.
If the variance of the outcome is at least as large under standard care as it is under the
optimal regime and the parametric estimator V̂n is at least as efficient as the sample mean
of n observations collected under the optimal policy, then
σ∗2 = lim
n→∞
Var
[√
n
{
V̂n − V (piopt)
}]
≤ lim
n→∞
Var
[
1√
n
n∑
i=1
{
Y ∗i (pi
opt)− V (piopt)}]
≤ lim
n→∞
Var
[
1√
n
n∑
i=1
{Y ∗i (pisoc)− V (pisoc)}
]
= Var {Y ∗(pisoc)} ,
where pisoc denotes standard of care. If one is unwilling to make the above assumptions, an
alternative would be to inflate the elicited value for Var {Y ∗(pisoc)} by a constant factor.
3.2 Projection-based sample size procedure
Despite a deluge of new estimators of optimal treatment regimes (see Zhang et al., 2017;
Zhou et al., 2017; Laber and Staicu, 2017; Tao and Wang, 2017, and references therein),
Q-learning with linear models remains among the most commonly used methods in practice.
This popularity can be partly attributed to: (i) the heavy use of linear models in seminal
papers on estimation of optimal treatment regimes (Murphy, 2003; Robins, 2004; Murphy,
2005b; Qian and Murphy, 2011); (ii) minimal requirements on the joint distribution of the
data-generating model; (iii) theoretical tractability (Chakraborty et al., 2009; Moodie et al.,
2010; Chakraborty et al., 2014; Laber et al., 2014); and (iv) good empirical performance
even under some forms of misspecification (Schulte et al., 2014). Thus, our second sample
size procedure is designed for the setting where analysts plan to estimate the optimal regime
using Q-learning with linear models. We do not assume that the analysis model is correctly
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specified nor do we impose any parametric structure on the generative model. However,
unlike the procedure described in the preceding section, the resultant sample size procedure
derived here relies on quantities that would be difficult to elicit from domain experts, we
therefore require that one has suitable pilot data available; such data could be historical or
collected as an internal pilot.
We assume that for t = 1, 2 one postulates models of the form Qt(ht, at;µt) = h
ᵀ
t,0µt,0 +
ath
ᵀ
t,1µt,1, where ht,0,ht,1 are summaries of ht and µt = (µ
ᵀ
t,0, µ
ᵀ
t,1)
ᵀ are unknown parameters.
Define µ∗2 = arg minµ2 P {Y −Q2(H2, A2;µ2)}2 and µ∗1 = arg minµ1 P{maxa2 Q2(H2, a2;µ∗2)
−Q1(H1, A1;µ1)}2. If (AN1) holds then, provided the requisite expectations exist, Q2(h2, a2) =
Q2(h2, a2;µ
∗
2); however, even if (AN1)-(AN4) hold, it need not follow that Q1(h1, a1) =
Q1(h1, a1;µ
∗
1) (Laber et al., 2014). Nevertheless, it is still meaningful to discuss the mean out-
come under the estimated optimal regime when these models are misspecified. Define the op-
timal regime under linearQ-learning with the above class of models as piQ,opt = (piQ,opt1 , pi
Q,opt
2 )
so that piQ,optt (ht) = arg maxat Qt(ht, at;µ
∗
t ).
1 Define µ̂2,n = arg minµ2 Pn {Y −Q2(H2, A2;µ2)}2
and µ̂1,n = arg minµ1 {maxa2 Q2(H2, a2; µ̂2,n)−Q2(H1, A1;µ1)}2. The estimated optimal de-
cision rule at time t is piQt,n(ht) = arg maxat Qt(ht, at; µ̂t,n).
It is well-known that V (piopt) is not a smooth functional of the generative model and
consequently standard approaches for inference, e.g., the bootstrap or series approximations,
will not hold without modification (Robins, 2004; Moodie et al., 2010; Chakraborty et al.,
2009, 2013, 2014; Laber et al., 2014; Luedtke and Van Der Laan, 2016). To derive a test which
satisfies (POW) we invert a variant of a projection confidence interval (Berger and Boos, 1994;
Robins, 2004) for V (piQ,opt); the interval we propose holds regardless of misspecification of the
Q-functions and does not require strong parametric assumptions on the underlying generative
model. This approach requires a confidence set for (µ∗1, µ
∗
2) which we construct as follows.
1 The notation piQ,opt is a bit misleading in that if the Q-functions are misspecified (which we allow) it
need not follow that V (piQ,opt) ≥ V Q(µ1, µ2) for all (µ1, µ2) ∈ Θ; we do not assume that piQ,opt satisfies such
an inequality. For additional discussion, see Qian and Murphy (2011) and references therein.
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Let C2 be as in (AN7) and let Ŵ2,n = {PnC2Cᵀ2}−1 PnC2Cᵀ2 (Y −Cᵀ2µ̂2,n) {PnC2Cᵀ2}−1 so
that Z2,n,ε =
{
µ2 : n(µ2− µ̂2,n)ᵀŴ−12,n(µ2− µ̂2,n) ≤ χ1−ε,dim(C2)
}
is a Wald-type (1−ε)×100
confidence set for µ∗2, where χ
2
q,k is the qth quantile of a chi-square random variable with k
degrees of freedom. For each µ2 define
µ∗1(µ2) = arg min
µ1
E
{
max
a2
Q2(H2, a2;µ2)−Q1(H1, A1;µ1)
}2
,
so that µ∗1(µ2) is denotes the population-level for the first-stage Q-function were it known
that µ∗2 = µ2; thus, µ
∗
1 = µ
∗
1(µ
∗
2). Define µ̂1,n(µ2) = arg minµ1 Pn{maxa2 Q2(H2, a2;µ2) −
Q1(H1, A1;µ1)}2, to be the least-squares estimator of µ∗1(µ2). Let C1 = (Hᵀ1,0, A1Hᵀ1,1)ᵀ
and define
W1,n(µ2) = {PnC1Cᵀ1}−1 PnC1Cᵀ1
{
max
a2
Q2(H2, a2;µ2)−Cᵀ1µ̂1,n(µ2)
}
{PnC1Cᵀ1}−1 .
A (1− ε)× 100% Wald-type confidence set for µ∗1(µ2) is
Z1,n,ε(µ2) =
{
µ1 : n [µ1 − µ̂1,n(µ2)]ᵀ Ŵ−11,n(µ2) [µ1 − µ̂1,n(µ2)] ≤ χ1−ε,dim(C1)
}
.
Thus, given ε1, ε2 ∈ (0, 1) with ϑ = ε1 + ε2 ≤ 1, a (1− ϑ)× 100% confidence set for (µ∗1, µ∗2)
is Ξn,1−ϑ = {(µ1, µ2) : µ2 ∈ Z2,n,1−ε2 and µ1 ∈ Z1,n,1−ε1(µ2)} .
For each µ1, µ2 define
δ(µ1, µ2) = 4Y 1A1H
ᵀ
1,1µ1,1>0
1
A2H
ᵀ
2,1µ2,1>0
+ 2
{
1
A1H
ᵀ
1,1µ1,1≤0 − (1/2)
}
max
a1
Q1(H1, a1;µ1)
+ 41
A1H
ᵀ
1,1µ1,1>0
{
1
A2H
ᵀ
2,1µ2,1≤0 − (1/2)
}
max
a2
Q2(H2, a2;µ2),
and subsequently define V̂ Qn (µ1, µ2) = Pnδ(µ1, µ2) and its population-level analog V Q(µ1, µ2) =
Eδ(µ1, µ2). Then, V̂n(µ̂n,1, µ̂2,n) is the augmented inverse probability weighted estimator
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of V (piQ,opt) (Zhang et al., 2013) and V Q(µ∗1, µ
∗
2) = V (pi
Q,opt) (see also Qian and Mur-
phy, 2011; Zhao et al., 2015). Define ς2(µ1, µ2) = E {δ(µ1, µ2)− Eδ(µ1, µ2)}2 and ς̂2n =
Pn {δ(µ1, µ2)− Pnδ(µ1, µ2)}2. For any fixed (µ1, µ2), it follows that
√
n
{
V̂ Qn (µ1, µ2)− V Q(µ1, µ2)
}
 Normal
{
0, ς2(µ1, µ2)
}
,
provided that Eδ2(µ1, µ2) <∞. Choose ϑ1 and ϑ2 such that ϑ1 +ϑ2 = α, then the proposed
α-level test for (POW) rejects when
inf
(µ1,µ2)∈Ξn,1−ϑ1
[
V̂ Qn (µ1, µ2)−
z1−ϑ2 ς̂n(µ1, µ2)√
n
]
≥ B0.
Under the null, V (piQ,opt) ≤ B0, so that the type I error is bounded above by
P
{
inf
(µ1,µ2)∈Ξn,1−ϑ1
[
V̂ Qn (µ1, µ2)−
z1−ϑ2 ς̂n(µ1, µ2)√
n
]
≥ V (piQ,opt)
}
≤ P
{
V̂ Qn (µ
∗
1, µ
∗
2)−
z1−ϑ2 ς̂n(µ
∗
1, µ
∗
2)√
n
≥ V (piQ,opt)
}
+ ϑ1 + o(1)
= P
{
√
n
[
V̂ Qn (µ
∗
1, µ
∗
2)− V Q(µ∗1, µ∗2)
ς̂n(µ∗1, µ
∗
2)
]
≥ z1−ϑ2
}
+ ϑ1 + o(1)
≤ ϑ1 + ϑ2 + o(1),
where the first inequality follows from P {(µ∗1, µ∗2) ∈ Ξn,1−ϑ1} ≥ 1−ϑ1+o(1). If ς̂n(µ1, µ2) > 0
with probability one for all (µ1, µ2) ∈ Θ, then it can be seen that the power of the proposed
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test is
P
{
inf
(µ1,µ2)∈Ξn,1−ϑ1
[
V̂ Qn (µ1, µ2)−
z1−ϑ2 ς̂n(µ1, µ2)√
n
]
≥ B0
}
= P
{
inf
(µ1,µ2)∈Ξn,1−ϑ1
[√
n
{
V̂ Qn (µ1, µ2)− V Q(µ1, µ2)
}
ς̂n(µ1, µ2)
+
√
n
{
V Q(µ1, µ2)−B0
}
ς̂n(µ1, µ2)
]
≥ z1−ϑ2
} (1)
≥ P
{
inf
(µ1,µ2)∈Ξn,1−ϑ1
(√
n
{
V̂ Qn (µ1, µ2)− V Q(µ1, µ2)
}
ς̂n(µ1, µ2)
+
min
[√
n
{
V Q(µ1, µ2)−B0
}
,
√
nη
]
ς̂n(µ1, µ2)
)
≥ z1−ϑ2
}
.
(2)
The minimum in (2) is analogous to plugging-in the smallest possible difference under the
alternative V (piQ,opt) − B0 ≥ η; see Remark 3.9 for additional discussion. The sampling
distribution of the test statistic under the alternative is complex and difficult to approximate
using series approximations; thus, to estimate a sample size that will yield the desired power,
we use the bootstrap.
3.2.1 Bootstrap power calculation
We assume that one has available pilot data Dn0 = {(X1,i, A1,i,X2,i, A2,i, Yi)}n0i=1 comprising
n0 i.i.d. trajectories from the same population from which trial participants will be drawn.
We estimate the power required in (POW) using the bootstrap with a resample size of n ≥ n0
and solve for the smallest n such that the estimated power exceeds a given threshold. In
our asymptotic analyses, we let both n and n0 diverge to infinity; however, as we anticipate
the trial sample size to be much larger than that of the pilot, we focus on an asymptotics in
which n goes to infinity “first.” We assume:
(PR1) EY 2||C2||2<∞ and E||C1||2||C2||2<∞;
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(PR2) EC1Cᵀ1 and EC2C
ᵀ
2 are finite and strictly positive definite;
(PR3) inf(µ1,µ2)∈Θ E {δ(µ1, µ2)− Eδ(µ1, µ2)}2 > 0 and sup(µ1,µ2)∈Θ E {δ(µ1, µ2)− Eδ(µ1, µ2)}2 <
∞;
(PR4) the classes F1 = {δ(µ1, µ2) : (µ1, µ2) ∈ Θ} and F2 = {δ2(µ1, µ2) : (µ1, µ2) ∈ Θ} are
Donsker;
(PR5) Eδ(µ1, µ2) is uniformly continuous in a neighborhood of (µ∗1, µ∗2).
The foregoing assumptions are standard in linear Q-learning and mirror those used in linear
regression (Laber et al., 2014).
Let P(b)n,n0 denote the bootstrap empirical distribution corresponding to a resample size of
n. For any functional Zn = f(P,Pn0) we define its bootstrap analog Z
(b)
n0,n = f
{
Pn0 ,P
(b)
n,n0
}
.
Let PB denote probabilities computed with respect the bootstrap distribution conditional
on the pilot data. The bootstrap estimator of the sample size required for (POW) is the
positive integer n which solves
PB
 inf(µ1,µ2)∈Ξ(b)n0,n,1−ϑ1
 √n
{
V̂
Q(b)
n0,n (µ1, µ2)− V̂ Qn0(µ1, µ2)
}
ς̂
(b)
n0,n(µ1, µ2)
+
min
[√
n
{
V̂ Qn0(µ1, µ2)−B0
}
,
√
nη
]
ς̂
(b)
n0,n(µ1, µ2)
 ≥ z1−ϑ2
 ≥ 1− γ
where ϑ1 + ϑ2 = α; the probability on the left hand side of the inequality can be computed
to desired precision by Monte Carlo methods. The following results establish consistency of
the bootstrap as n0 and n diverge.
Theorem 3.7. Assume (C1)-(C3) and (PR1)-(PR4). Let ϑ1 ∈ (0, 1) be fixed. Let κ, K > 0
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be arbitrary, then
lim
n,n0→∞
P
(
sup
|v|≤K
∣∣∣∣∣PB
 inf
(µ1,µ2)∈Ξ(b)n0,n,1−ϑ1
√
n
{
V̂
Q(b)
n0,n (µ1, µ2)− V̂ Qn0(µ1, µ2)
}
ς̂
(b)
n0,n(µ1, µ2)
≥ v

− P
 inf
(µ1,µ2)∈Ξn,1−ϑ1
√
n
{
V̂ Qn (µ1, µ2)− V Q(µ1, µ2)
}
ς̂n(µ1, µ2)
≥ v
 ∣∣∣∣∣ > κ
)
= 0.
The preceding result does not include
√
n
{
V Q(µ1, µ2)−B0
}
/ς̂n(µ1, µ2) (or its bootstrap
analog) because, under the alternative, provided V (µ1, µ2) > B0 for all (µ1, µ2) in a suffi-
ciently small neighborhood of (µ∗1, µ
∗
2), this term (and its bootstrap analog) will diverge to
infinity so that the conclusion of the above theorem will hold trivially. The following result
characterizes the limiting tail behavior of this term; the factor of
√
n on the right-hand-
side of each probability assignment reflects the fact that, under the alternative, we expect
√
n
{
V Q(piQ,opt)−B0
}
to diverge at rate
√
n.
Theorem 3.8. Assume (C1)-(C3) and (PR1)-(PR4). Let ϑ1 ∈ (0, 1) and η ≥ 0 be fixed. In
addition, assume that n0 →∞ as n→∞ and that there exists c > 0 so that inf(µ1,µ2)∈Ω ς̂n(µ1, µ2) ≥
c. Let κ, K > 0 be arbitrary then
lim
n,n0→∞
P
(
sup
|v|≤K
∣∣∣∣∣PB
 inf
(µ1,µ2)∈Ξ(b)n0,n,1−ϑ1
min
[√
n
{
V̂
Q,(b)
n0,n (µ1, µ2)−B0
}
,
√
nη
]
ς̂
(b)
n0,n(µ1, µ2)
≥ √nv

− P
 inf
(µ1,µ2)∈Ξn,1−ϑ1
min
[√
n
{
V̂ Qn (µ1, µ2)−B0
}
,
√
nη
]
ς̂n(µ1, µ2)
≥ √nv
 ∣∣∣∣∣ > κ
)
= 0.
To choose n so that (OPT) holds asymptotically we make use of the following bound.
For any (possibly data-dependent) sequence (µ˜1,n, µ˜2,n) ∈ Ξn,1−ϑ1 such that V̂ Qn (µ∗1, µ∗2) ≤
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V̂ Qn (µ˜1,n, µ˜2,n) + oP (1/
√
n) it follows that
P
[
V Q(µ˜1,n, µ˜2,n) ≥ V Q(piQ,opt) + inf
(µ1,µ2)∈Ξn,1−ϑ1
{
V̂ Qn (µ1, µ2)− V Q(µ1, µ2)
}
− sup
(µ1,µ2)∈Ξn,1−ϑ1
{
V̂ Qn (µ1, µ2)− V Q(µ1, µ2)
}]
≥ 1− ϑ1 + o(1).
Thus, if Qn,1−ϑ2,1−ϑ1 is the (1− ϑ2) quantile of
inf
(µ1,µ2)∈Ξn,1−ϑ1
{
V̂ Qn (µ1, µ2)− V Q(µ1, µ2)
}
− sup
(µ1,µ2)∈Ξn,1−ϑ1
{
V̂ Qn (µ1, µ2)− V Q(µ1, µ2)
}
then choosing ϑ1 + ϑ2 ≤ ζ and n such that Qn,1−ϑ1,1−ϑ2/
√
n ≤  ensures that (OPT) holds
asymptotically. Of course, Qn,,1−ϑ1,1−ϑ2 is unknown so we estimtate it using the bootstrap,
i.e., we select n so that Q
(b)
n0,n,1−ϑ1,1−ϑ2/
√
n ≤ .
Remark 3.9. To estimate the power at a given sample size one could use the bootstrap
analog of (1). Indeed, the preceding theoretical results can be easily modified to hold without
the min operation. However, the required sample size derived from (1) will be based on an
estimated effect size rather than the minimal effect size of interest, η. A consequence of
using the estimated effect size is that as the true effect size increases the estimated required
sample size will decrease keeping the power fixed at (approximately) (1−γ)×100. However,
in application, it desirable to have power (1 − γ) × 100 at effect size η but larger power if
the effect size exceeds η. Taking the minimum, as in (2), ensures that the power diverges to
one as the true effect size grows large.
4 Simulation experiments
We examine the finite sample performance of the proposed sample size procedures using a
series of simulation experiments. Performance is measured in terms of the proposed criteria
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(POW) and (OPT). For each generative model, we also compute the number of samples
required to compare the mean outcomes under standard care to that under the fixed regimes
pi i,j, i, j ∈ {−1, 1}, where pii,j1 (h1) ≡ i and pii,j2 (h2) ≡ j. This comparison allows us to
evaluate how much the sample size must be inflated to estimate and/or evaluate an opti-
mal dynamic treatment regime relative to the comparison of fixed and embedded regimes
(Almirall et al., 2012).
We first consider a generative model in which the assumptions (AN1)-(AN8) for the
normality-based sample size procedure hold. This generative model is as follows:
X1 ∼ N4{0,ΩAR1(0.5)}, HT1,0 = (1, X1,0),
HT1,1 = (1, X1,1), H
T
1,2 = (1, X1,2),
HT1,3 = (1, X1,3), A1, A2 ∼i.i.d. Unif{−1, 1},
φ1, φ2, υ ∼i.i.d. N(0, 1), X2,0 = HT1,0µ∗1,0 + A1HT1,1µ∗1,1 + φ1,
X2,1 = H
T
1,2µ
∗
2,0 + A1H
T
1,3µ
∗
2,1 + φ2, H
T
2,0 = (1, X1,0, A1, X2,0),
HT2,1 = (1, X1,2, A1, X2,1), Y = H
T
2,0β
∗
2,0 + A2H
T
2,1β
∗
2,1 + υ,
where ΩAR1(0.5) is an autoregressive covariance matrix such that {ΩAR1(0.5)}ij = 0.5|i−j|.
Let pifixed,opt denote the optimal fixed regime such that pifixed,opt = pi i
∗,j∗ , where i∗, j∗ =
arg maxi,j∈{−1,1} V (pi i,j). We examine the performance of the proposed methods under pa-
rameter values which result in the following relationships between pifixed,opt, piopt, and B0:
1. V (piopt) = V (pifixed,opt) = B0 + η;
2. V (piopt)− 0.5η = V (pifixed,opt) = B0 + η;
3. V (piopt)− η = V (pifixed,opt) = B0 + η;
4. V (piopt)− 2η = V (pifixed,opt) = B0 + η.
Define ∆ =
{
V (piopt)− V (pifixed,opt)} /η to be a measure of benefit associated with imple-
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menting an optimal dynamic treatment regime relative to the optimal fixed regime. It can be
seen that ∆ ranges from zero to two across the above scenarios. Parameter settings indexing
the generative model which yield these values of ∆ when η = 1 are:
1. µ1,0 = (−1, 1), µ1,1 = (4, 1), µ2,0 = (−0.4,−1), µ2,1 = (4, 1), β∗2,0 = (0.5, 0.5,−1, 1) and
β∗2,1 = (1, 0.5, 0.5, 1);
2. µ1,0 = (−1, 1), µ1,1 = (4, 1), µ2,0 = (−0.4,−1), µ2,1 = (−4, 1), β∗2,0 = (0.5, 0.5,−1, 1)
and β∗2,1 = (1,−0.9, 0.5, 1);
3. µ1,0 = (−1, 1), µ1,1 = (4, 1), µ2,0 = (−0.4,−1), µ2,1 = (−4, 1), β∗2,0 = (0.5, 0.5,−1, 1)
and β∗2,1 = (1,−1.75, 0.5, 1);
4. µ1,0 = (−1, 1), µ1,1 = (4, 1), µ2,0 = (−0.4,−1), µ2,1 = (−4, 1), β∗2,0 = (0.5, 0.5,−1, 1)
and β∗2,1 = (1,−3.25, 0.5, 1).
Let γ = 0.1, α = 0.05, ζ = 0.1, and  = 0.3. Thus, if (POW) holds, then an α-level
test of H0 : V (pi
opt) ≤ B0 will have approximately 90% power, and if (OPT) holds, then
P [E {Y ∗(pin)|Dn} ≥ V (piopt)− 0.3] ≥ 0.9+o(1). Recall that the normality-based sample size
procedure requires specification of σ∗. We consider three possibilities: (i) σ∗ is known, e.g.,
correctly elicited from domain experts; (ii) σ∗ is estimated using a pilot study of n0 patients;
and (iii) σ∗ is estimated using the ad hoc procedure presented in Remark 3.9 using a sample
of n0 subjects treated under standard care wherein we assume that patients are assigned
the optimal treatment 80% of the time and suboptimal treatment the remaining 20% of the
time. To form a baseline for comparison, we also compute the sample size required to power
a test of the null V (pifixed,opt) ≤ B0 against the alternative V (pifixed,opt) > B0 where it is
assumed that pifixed,opt is known a priori as is Var
{
Y ∗(pifixed,opt)
}
; this reflects the common
practice of comparing a fixed regime against standard of care or another fixed regime. All
results are based on 500 Monte Carlo replications.
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Table 1 displays the average estimated sample size and its operating characteristics across
the four settings of the proposed generative model and three approaches to selecting σ∗ when
sizing for just condition (POW). Table 2 displays the same results when sizing for condition
(OPT). A table of results when sizing for both jointly is contained in the Supplemental
Materials. In the case where ∆ = 0, the optimal treatment regime provides no benefit over
the optimal fixed regime, thus, this setting reflects a worst-case in terms of the conservatism
of sizing for (POW) and (OPT) rather than simply sizing to identify the optimal fixed
regime; in this case, the proposed sample size procedure attains nominal levels for (POW)
and (OPT) at the cost of an inflated sample size. However, as ∆ increases, so that the
benefits of personalizing treatment relative to a fixed regime also increase, it can be seen that
the sample size required for (POW) and (OPT) can (perhaps surprisingly) be considerably
smaller than required for identifying an optimal embedded regime provided that one has a
high-quality estimate for σ∗ either through elicitation or a pilot study. Table 2 has power
1.0 for all cases considered which is a consequence of using an upper bound on the difference
between the value of the estimated regime and the optimal regime. One could potentially
explore data-adaptive adjustments, e.g., the double bootstrap, to reduce this excess power.
We also examined the performance of the normality-based sample size when the pos-
tulated modeling assumptions are violated. For these simulations, we used the following
generative model:
X1 ∼ N(0, 1), A1, A2 ∼i.i.d. Unif{−1, 1},
φ ∼ t3, X2 = µ∗0 + µ∗1X1 + µ∗2A1 + µ∗3A1X1 + µ∗4X21 + φ,
H2,0 = (1, X1, A1, X1A1, X2), H2,1 = (1, A1, X2),
υ ∼ N(0, 1), Y = HT2,0β∗2,0 + A2HT2,1β∗2,1 + υ.
As previously, we let V (piopt) −∆η = V (pifixed,opt) = B0 + η and consider ∆ ∈ {0, 0.5, 1, 2}.
We set µ∗ = (1, 0.5, 0.5, 0.1, 1) and choose β∗ as follows:
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Table 1: Estimated power (POW) under a correctly specified generative model using the
normality-based sample size procedure at a nominal level of 90. To form a baseline for
comparison, n̂fixed, shows the required sample size to compare the optimal embedded regime
with standard of care.
∆ Method for σ∗ n0 (POW) (OPT) nˆfixed Enˆ Med(nˆ) SDnˆ
0 known 50 90.0 - 74 130 − −
0 pilot study 50 87.2 - 74 100.57 99 26.74
0 surrogate 50 98.6 - 74 186.44 185 44.65
0.5 known 50 100 - 111 124 − −
0.5 pilot study 50 99.8 - 111 132.14 131 29.39
0.5 surrogate 50 100 - 111 164.06 159 46.60
1 known 50 100 - 151 134 − −
1 pilot study 50 100 - 151 160.43 158 33.11
1 surrogate 50 100 - 151 203.78 199.5 62.16
2 known 50 100 - 251 165 − −
2 pilot study 50 100 - 251 235.47 233 46.14
2 surrogate 50 100 - 251 280.04 275 82.16
1. ∆ = 0, β∗2,0 = (1, 0.5, 0.5, 0.5, 1.5), β
∗
2,1 = (−1,−1, 0);
2. ∆ = 0.5, β∗2,0 = (1, 0.5, 0.5, 0.5, 1.5), β
∗
2,1 = (−1,−1, 0.55);
3. ∆ = 1, β∗2,0 = (1, 0.5, 0.5, 1, 1.5), β
∗
2,1 = (−1,−1, 0.65);
4. ∆ = 2, β∗2,0 = (1, 0.5, 0.5, 2.3, 1.5), β
∗
2,1 = (−1,−1, 0.71).
The average sample size and operating characteristics of the normality-based sample size
procedure when sizing for condition (POW) are displayed in Table 3 whereas the average
sample size and characteristics for condition (OPT) are in Table 4. Results for sizing to
guarantee both conditions jointly are contained in the Supplemental Materials. The proposed
method continues to attain nominal levels for ∆ ≥ 1, but is underpowered when using a pilot
study to estimate σ∗ and there is little or no benefit to the optimal regime over the optimal
embedded regime.
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Table 2: Estimated concentration (OPT) under a correctly specified generative model using
the normality-based sample size procedure at a nominal level of 90. To form a baseline for
comparison, n̂fixed, shows the required sample size to compare the optimal embedded regime
with standard of care.
∆ Method for σ∗ n0 (POW) (OPT) nˆfixed Enˆ Med(nˆ) SDnˆ
0 known 50 - 100 74 277 − −
0 pilot study 50 - 100 74 204.51 199.5 60.60
0 surrogate 50 - 100 74 394.63 390 90.04
0.5 known 50 - 100 111 263 − −
0.5 pilot study 50 - 100 111 269.91 264 62.58
0.5 surrogate 50 - 100 111 353.35 343.5 98.09
1 known 50 - 100 151 285 − −
1 pilot study 50 - 100 151 335.69 332.5 69.93
1 surrogate 50 - 100 151 431.93 420 130.70
2 known 50 - 100 251 352 − −
2 pilot study 50 - 100 251 495.52 491 92.61
2 surrogate 50 - 100 251 605.82 578.5 176.10
We also applied the projection-based sample size procedure to the two classes of gener-
ative models described above. Each Monte Carlo replication consists of the following steps.
We first generate a pilot study of size n0. The bootstrap method described in Section 3.2 is
used to calculate the minimum sample size nˆ(Dn0) to achieve power (1 − γ) × 100% using
100 bootstrap replications across a grid of potential sample sizes and then using nonlinear
least squares to regress the estimated power on the sample sizes. Let γ = 0.1, ϑ1 = 0.01,
and ϑ2 = 0.04. Which corresponds to 90% power for a test with 5% significance level based
on a confidence interval for V (piopt) that is being constructed using a 99% confidence set for
(µ∗1, µ
∗
2) and a 96% interval for V (µ1, µ2) for each fixed value of (µ1, µ2). Table 5 displays
the results under the normal generative model when sizing for condition (POW); in some
cases the pilot study shows no benefit to tailoring treatment, i.e., V̂n0 ≤ B0, in which case
n̂(D0) = +∞. Table 6 displays the results when sizing for condition (OPT) under the normal
generative model.
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Table 3: Estimated power (POW) under a model which violated the normality assumptions
using the normality-based sample size procedure at a nominal level of 90. To form a baseline
for comparison, n̂fixed, shows the required sample size to compare the optimal embedded
regime with standard of care.
∆ Method for σ∗ n0 (POW) (OPT) nˆfixed Enˆ Med(nˆ) SDnˆ
0 known 50 99.2 - 70 275 − −
0 pilot study 50 72.4 - 70 77.96 59 74.25
0 surrogate 50 92.8 - 70 158.91 148 65.31
0.5 known 50 100 - 35 228 − −
0.5 pilot study 50 80.0 - 35 65.14 46 79.77
0.5 surrogate 50 98.2 - 35 151.95 131 78.04
1 known 50 100 - 47 296 − −
1 pilot study 50 89.0 - 47 77.77 56.5 72.61
1 surrogate 50 99.6 - 47 194.20 166 281.04
2 known 50 100 - 103 407 − −
2 pilot study 50 99.4 - 103 139.88 118.5 90.88
2 surrogate 50 100 - 103 252.01 227.5 110.40
Table 7 show the results for when the projection-based method when sizing for condition
(POW) is applied to the data generating model for which the normality assumptions do
not hold. The results of sizing for condition (OPT) for the model which the normality
assumptions do not hold is contained in Table 8. It can be seen that for ∆ ≥ 0.50 the
proposed procedure attains nominal power for (POW) for both generative models.
5 Discussion
We proposed two sample size procedures for two-stage SMARTs when the objective is es-
timation and evaluation of an optimal dynamic treatment regime. These procedurs can be
used to design SMARTs or conduct power analyses for observational studies. Furthermore,
a comparison of the sample size required for construction of a high-quality estimator of an
optimal treatment regime with the sample size required for comparison of fixed treatment
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Table 4: Estimated concentration (OPT) under a model which violated the normality
assumptions using the normality-based sample size procedure at a nominal level of 90. To
form a baseline for comparison, n̂fixed, shows the required sample size to compare the optimal
embedded regime with standard of care.
∆ Method for σ∗ n0 (POW) (OPT) nˆfixed Enˆ Med(nˆ) SDnˆ
0 known 50 - 100 70 586 − −
0 pilot study 50 - 89.4 70 161.96 122 147.53
0 surrogate 50 - 100 70 339.32 317.5 134.60
0.5 known 50 - 100 35 485 − −
0.5 pilot study 50 - 85.6 35 119.20 87 118.01
0.5 surrogate 50 - 100 35 322.16 285.5 190.63
1 known 50 - 100 47 630 − −
1 pilot study 50 - 0.88 47 186.41 142.5 159.20
1 surrogate 50 - 0.99 47 390.41 344.5 191.12
2 known 50 - 100 103 866 − −
2 pilot study 50 - 99.6 103 296.34 241 211.56
2 surrogate 50 - 100 103 537.83 490.5 277.45
sequences (or another simple comparison commonly used to size a SMART) can generate
new insights into the cost of precision medicine in a given problem domain.
The proposed procedures were developed under two extremes in terms of the structure
imposed on the underlying generative model. At one extreme, we assumed correctly speci-
fied parametric models for several functionals of the generative model including the optimal
regime; and, at the other extreme, we only imposed moment conditions on a possibly misspec-
ified analysis model. There is large class of intermediate models that could be constructed
from these two base approaches. Furthermore, while the proposed approaches focused on
regression-based estimators they can be extended to classification-based or direct-search es-
timators (Orellana et al., 2010; Zhang et al., 2012; Zhao et al., 2012; Zhang et al., 2012,
2013; Zhao et al., 2015; Zhou et al., 2017; Zhao et al., 2015; Laber and Zhao, 2015) which
are becoming increasingly popular; we leave the details of this extension to future work.
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Table 5: Estimated power (POW) under a model for which the normality assumptions
hold using the projection-based sample size procedure at a nominal level of 90. To form
a baseline for comparison, n̂fixed, shows the required sample size to compare the optimal
embedded regime with standard of care.
∆ n0 (POW) (OPT) nˆ
fixed Enˆ(Dn0) Med{nˆ(Dn0)} SDnˆ(Dn0) P {nˆ(D0) =∞}
0 50 85.17 - 74 381.94 342.5 112.46 0.42
0.5 50 99.13 - 111 316.01 292.5 83.89 0.21
1 50 99.73 - 151 312.39 299 71.96 0.17
2 50 100 - 251 364.95 361.5 62.78 0.06
Table 6: Estimated concentration (OPT) under a model for which the normality assump-
tions hold using the projection-based sample size procedure at a nominal level of 90. To
form a baseline for comparison, n̂fixed, shows the required sample size to compare the opti-
mal embedded regime with standard of care.
∆ n0 (POW) (OPT) nˆ
fixed Enˆ(Dn0) Med{nˆ(Dn0)} SDnˆ(Dn0)
0 50 - 100 74 114.73 113 9.72
0.5 50 - 100 111 107 106 9.59
1 50 - 99.8 151 112.22 111 10.69
2 50 - 99.4 251 124.3 123 13.22
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